C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	311	278	289	1,566	1,426	-
Market Cap Growth	263.89%	-3.60%	-81.55%	9.83%	-	-
Enterprise Value	119	92	97	1,296	1,074	-79
PE Ratio	-	-2.10	-2.25	-18.66	-21.49	-
PS Ratio	15.52	13.42	9.29	34.20	42.95	-
PB Ratio	1.20	1.13	1.00	4.02	5.08	-
P/FCF Ratio	-6.03	-2.57	-2.59	-17.74	-21.00	-
P/OCF Ratio	-6.10	-2.61	-2.73	-18.00	-21.20	-
EV/Sales Ratio	5.94	4.45	3.11	28.31	32.36	-3.71
EV/EBITDA Ratio	-3.18	-0.76	-0.82	-16.44	-17.08	2.60
EV/EBIT Ratio	-2.97	-0.71	-0.77	-15.85	-16.34	2.38
EV/FCF Ratio	-3.97	-0.85	-0.87	-14.69	-15.82	-1.46
Debt / Equity Ratio	0.27	0.29	0.30	0.11	0.08	-0.12
Debt / EBITDA Ratio	-0.60	-0.58	-0.74	-0.54	-0.36	-0.45
Debt / FCF Ratio	-0.75	-0.65	-0.78	-0.49	-0.34	0.25
Quick Ratio	5.00	6.29	6.31	6.21	8.64	2.91
Current Ratio	5.08	6.34	6.46	6.36	8.69	2.88
Asset Turnover	0.05	0.06	0.07	0.10	0.13	0.16
Interest Coverage	-161.70	-94.57	-56.84	-38.11	-53.48	-
Return on Equity (ROE)	-52.90%	-55.30%	-38.90%	-22.90%	-78.60%	44.40%
Return on Assets (ROA)	-34.00%	-35.80%	-27.00%	-17.50%	-25.60%	-32.20%
Return on Capital (ROIC)	-41.16%	-43.85%	-34.42%	-18.99%	-19.90%	36.10%
Earnings Yield	-40.54%	-47.58%	-44.37%	-5.36%	-4.65%	-
FCF Yield	-29.89%	-38.98%	-38.58%	-5.64%	-4.76%	-
Buyback Yield / Dilution	-39.57%	-1.59%	-6.12%	-304.93%	-728.80%	87.42%
Total Shareholder Return	-39.57%	-1.59%	-6.12%	-304.93%	-728.80%	87.42%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).